Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma

ConclusionsContinued pembrolizumab administration beyond progression might be beneficial in patients with metastatic UC who were clinically stable.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research